Compare FVRR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | AMRN |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | Israel | Ireland |
| Employees | 528 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 342.8M |
| IPO Year | 2019 | 1998 |
| Metric | FVRR | AMRN |
|---|---|---|
| Price | $8.96 | $14.26 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $18.43 | $12.00 |
| AVG Volume (30 Days) | ★ 891.9K | 53.4K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | $1.26 |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $8.75 | $12.96 |
| 52 Week High | $28.00 | $20.90 |
| Indicator | FVRR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 45.92 |
| Support Level | $8.75 | $13.47 |
| Resistance Level | $11.57 | $14.49 |
| Average True Range (ATR) | 0.47 | 0.43 |
| MACD | -0.12 | 0.08 |
| Stochastic Oscillator | 16.28 | 66.37 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.